Blueprint Medicines Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BLUEPRINT MEDICINES, and what generic alternatives to BLUEPRINT MEDICINES drugs are available?
BLUEPRINT MEDICINES has one approved drug.
There are seven US patents protecting BLUEPRINT MEDICINES drugs.
There are fifty-four patent family members on BLUEPRINT MEDICINES drugs in thirty-three countries and sixteen supplementary protection certificates in fourteen countries.
Summary for Blueprint Medicines
| International Patents: | 54 |
| US Patents: | 7 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Blueprint Medicines
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-002 | Jan 9, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-003 | Jan 9, 2020 | RX | Yes | Yes | 11,964,980 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-005 | Jun 16, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-004 | Jun 16, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-004 | Jun 16, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-004 | Jun 16, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Blueprint Medicines Drugs
Supplementary Protection Certificates for Blueprint Medicines Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3057969 | PA2021003,C3057969 | Lithuania | ⤷ Sign Up | PRODUCT NAME: AVAPRITINIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/20/1473 20200924 |
| 3057969 | 2190008-9 | Sweden | ⤷ Sign Up | PRODUCT NAME: AVAPRITINIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/20/1473 20200925 |
| 3057969 | SPC/GB21/020 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: AVAPRITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK PLGB52115/0001-0003 20200925; UK EU/1/20/1473(NI) 20200925 |
| 3057969 | C03057969/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: AVAPRITINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68294 06.07.2023 |
| 3057969 | 301094 | Netherlands | ⤷ Sign Up | PRODUCT NAME: AVAPRITINIB EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/20/1473 20200925 |
| 3057969 | 21C1013 | France | ⤷ Sign Up | PRODUCT NAME: AVAPRITINIB ET LES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/20/1473 20200925; FIRST REGISTRATION: - EU/1/20/1473 20200925 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
